Cetuximab enhances the anti-proliferative effect of trastuzumab in ERBB2 over-expressing breast cancer cells - Preliminary study

Klinicka Onkologie

Volumn 24, Issue 5, 2011, Pages 356-360

  Überall, Ivo ^a   Krizova K ^a   Steigerova J ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Breast cancer; Cetuximab; Dual inhibition; ERBB receptors; Trastuzumab

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CELL STRAIN MCF 7; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 80155209852     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Lohrisch C, Piccart M. An overview of HER-2. Semin Oncol 2001; 28 (6 Suppl 18): 3-11.
2. Berkovcové J, Hajdúch M, Dziechcierková M et al. Predikce účinnosti tyrozikinázových inhibitorů EGFR1 v léčbě nemalobuněčných plicních karcinomů. Klin Oncol 2006; 19(3): 171-176.
3. Bouchalova K, Cizkova M, Cwiertka K et al. Triple negative breast cencer - current status and prospective tergeted treatment based on HER1 (EGFR), TOP2 and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153(1): 13-17.
4. Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 2004; 30(1): 1-17. (Pubitemid 38240085)
5. Mass RD, Press MF, Anderson S et al. Evaluation of clinical outcomes according to HER-2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005, 6(3): 240-246. (Pubitemid 47050800)
6. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235(4785): 177-182. (Pubitemid 17231334)
7. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999; 18(3): 731-738 (Pubitemid 29080330)
8. Moulder SL, Yakes TM, Muthuswamy SK et al. Epidermal growth facor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER/neu (ERBB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001, 61(24): 8887-8895. (Pubitemid 34013905)
9. Moasser MM, Basso A, Averbuch SD et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and supresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001, 61 (19): 7184-7188. (Pubitemid 32946513)
10. Normanno N, Campiglio M, De LA et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002; 13(1): 65-72. (Pubitemid 34436727)
11. Ye D, Mendelsohn J, Fan Z. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kp1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells Clin Cancer Res 1999; 5(8): 2171-2177. (Pubitemid 29399274)
12. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007; 43(3): 481-489. (Pubitemid 46178540)
13. Brockhoff G, Heckel B, Schmidt-Bruecken E et al. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT-474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 2007; 40(4): 488-507. (Pubitemid 47063288)
14. Cuello M, Effenberg SA, Clark AS et al. Down-regulation of the ERBB2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress ERBB2. Cancer Res 2001, 61 (12): 4892-4900. (Pubitemid 32691907)
15. Romijn JC, Verkoelen CF, Schroeder FH. Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 1998; 12(1): 99-110.
16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 1967; 72: 248-254.
17. Badache A, Hynes NE. A new therapeutic antibody masks ERBB2 to its partners. Cancer Cell 2004; 5(4): 299-301.
18. Mellinghoff IK, Vivanco I, Kwon A et al. HER2/neu kinase-dependent modulation of androgen receptor function through effect on DNA binding and stability. Cancer Cell 2004, 6(5): 517-527. (Pubitemid 39469987)
19. Lenferink AE, Busse D, Flanagan M et al. ERBB2/neu kinase modulates cellular p27(Kip 1) and cyclin D1 through multiple signaling pathways. Cancer Res 2001, 61(17): 6583-6591. (Pubitemid 32783268)
20. Alimandi M, Romano A, Curia MC et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995; 10(9): 1813-1821.
21. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64(7): 2343-2346. (Pubitemid 38523885)
22. Kawada M, Yamagoe S, Murakami Y et al. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway Oncogene 1997; 15(6): 629-637. (Pubitemid 27389926)
23. Rivard N, Boucher MJ, Asselin C et al. MAP kinase cascade is reguired for p27 downragulation and S phase entry in fibroblastis and epithelial cells. Ann J Physiol 1999; 277(4 Pt 1): C652-C664. (Pubitemid 29525904)
24. Lane HA, Beuvink I, Motoyama AB et al. ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000; 20(9): 3210-3223. (Pubitemid 30215033)